Table 1.

Pretransplantation characteristics of patients


Patient no.

Sex

Age, y

Type of MS

EDSS

Disease duration, mo

Prior therapy
1   F   34   SP   8.0   163   IFN-1β, GA  
2   F   49   SP   6.5   277   INF-1β, MPSE, bee stings  
3   M   37   PP   6.0   10   MPSE  
4   F   46   RR   7.0   97   IFN-α, IFN-1β, GA, MPSE  
5   M   35   SP   6.0   24   IFN-1α, IFN1β, GA  
6   F   37   SP   6.0   69   IFN-1α, IFN-1β, GA  
7   F   51   SP   7.0   69   IFN-1β  
8   F   48   SP   8.0   79   IFN-1β  
9   F   57   SP   7.0   82   IFN-1α, IFN1β, GA  
10   M   51   PP   6.5   84   IFN-α, IFN-1β, MPSE  
11   F   47   SP   8.0   107   IFN-1α, IFN1β, GA  
12   M   38   SP   6.5   119   IFN-1α, IFN1β  
13   F   29   SP   6.5   138   IFN-α, IFN-1β, GA, MPSE  
14   M   43   PP   7.0   110   IFN-1β  
15   M   27   PP   7.5   48   IFN-1β, GA  
16   M   60   SP   7.5   50   IFN-α, IFN-1β, MPSE  
17   F   44   SP   7.5   188   IFN-α, GA, Ctx  
18   F   47   SP   7.5   149   IFN-1β, Mtx  
19   M   29   SP   5.0   144   IFN-α  
20   M   36   PP   6.5   48   MPSE  
21   M   45   SP   8.0   83   IFN-1β, GA  
22   M   44   PP   6.5   94   IFN-α, IFN-1β, Imuran  
23   M   52   PP   5.0   49   IFN-α  
24   M   28   PP   7.0   12   IFN-α, IFN-1β, IVIG, Prd, Nv  
25   F   47   SP   8.0   179   IFN-1β, Ctx, Prd  
26   M   41   SP   7.0   195   IFN-α, IFN-1β, IVIG  
Median
 

 
41
 

 
7.0
 
84
 

 

Patient no.

Sex

Age, y

Type of MS

EDSS

Disease duration, mo

Prior therapy
1   F   34   SP   8.0   163   IFN-1β, GA  
2   F   49   SP   6.5   277   INF-1β, MPSE, bee stings  
3   M   37   PP   6.0   10   MPSE  
4   F   46   RR   7.0   97   IFN-α, IFN-1β, GA, MPSE  
5   M   35   SP   6.0   24   IFN-1α, IFN1β, GA  
6   F   37   SP   6.0   69   IFN-1α, IFN-1β, GA  
7   F   51   SP   7.0   69   IFN-1β  
8   F   48   SP   8.0   79   IFN-1β  
9   F   57   SP   7.0   82   IFN-1α, IFN1β, GA  
10   M   51   PP   6.5   84   IFN-α, IFN-1β, MPSE  
11   F   47   SP   8.0   107   IFN-1α, IFN1β, GA  
12   M   38   SP   6.5   119   IFN-1α, IFN1β  
13   F   29   SP   6.5   138   IFN-α, IFN-1β, GA, MPSE  
14   M   43   PP   7.0   110   IFN-1β  
15   M   27   PP   7.5   48   IFN-1β, GA  
16   M   60   SP   7.5   50   IFN-α, IFN-1β, MPSE  
17   F   44   SP   7.5   188   IFN-α, GA, Ctx  
18   F   47   SP   7.5   149   IFN-1β, Mtx  
19   M   29   SP   5.0   144   IFN-α  
20   M   36   PP   6.5   48   MPSE  
21   M   45   SP   8.0   83   IFN-1β, GA  
22   M   44   PP   6.5   94   IFN-α, IFN-1β, Imuran  
23   M   52   PP   5.0   49   IFN-α  
24   M   28   PP   7.0   12   IFN-α, IFN-1β, IVIG, Prd, Nv  
25   F   47   SP   8.0   179   IFN-1β, Ctx, Prd  
26   M   41   SP   7.0   195   IFN-α, IFN-1β, IVIG  
Median
 

 
41
 

 
7.0
 
84
 

 

F indicates female; SP, secondary progressive; IFN-β interferon-β (Betaseron); GA, glatiramer acetate; MPSE, methylprednisolone; M, male; PP, primary progressive; RR, relapsing-remitting; IFN-α, interferon-α (Avonex); Ctx, cyclophosphamide; Mtx, methotrexate; IVIG, intravenous immunoglobulin; Prd, prednisone; and Nv, mitoxantrone.

or Create an Account

Close Modal
Close Modal